Investors
AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap
-
![Quote]()
Continued high margins and increased acquisition activity
Fredrik Dalborg, President and CEO
comments by the ceoAddLife is starting 2026 with continued high margins. After a strong finish to 2025, sales were somewhat subdued at the beginning of the year, but the quarter ended with good growth and the underlying trends are clearly positive. With a strong balance sheet, the pace of acquisitions has increased and two acquisitions were completed in March and April.
![fredrik-dalborg-q3-2024.jpg]()
AddLife creates value
The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.
AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.
AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.
AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.
Subscribe
Your subscription is now saved and you will receive an email to verify your email address and activate the subscription.